Novel PET radiopharmaceutical shows promising results in first-in-humans study
The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed at the University of Turku, Finland, have been published. The compound, which targets the vascular adhesion protein 1 (VAP-1) that regulates inflammatory cell traffic, is the first radiopharmaceutical that has been developed completely in Finland and has advanced to clinical trials. In the study that started with healthy volunteers, the radiopharmaceutical was found to be well tolerated and safe.
The radiopharmaceutical is 68Ga-labelled Siglec-9 peptide.
The dose of the radiopharmaceutical used in PET imaging is thousands of times lower when compared with the regular drugs. Studies with new radiopharmaceuticals are therefore safer than the usual drug research studies."